Maze Therapeutics Files IPO Amendment

Ticker: MAZE · Form: S-1/A · Filed: Jan 30, 2025 · CIK: 1842295

Maze Therapeutics, Inc. S-1/A Filing Summary
FieldDetail
CompanyMaze Therapeutics, Inc. (MAZE)
Form TypeS-1/A
Filed DateJan 30, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$15.00, $17.00, $150 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, sec-filing, biotech

TL;DR

Maze Therapeutics filed an S-1/A for its IPO. Details updated.

AI Summary

Maze Therapeutics, Inc. filed an S-1/A amendment on January 30, 2025, for its initial public offering. The company, incorporated in Delaware, is seeking to register an unspecified number of shares. The filing provides updated information for potential investors regarding its business, financial condition, and the terms of the offering.

Why It Matters

This filing provides updated details for investors considering an investment in Maze Therapeutics' initial public offering, impacting potential share pricing and company valuation.

Risk Assessment

Risk Level: medium — As a pre-IPO filing, it indicates the company is seeking capital and is subject to the inherent risks of public market offerings and the biotechnology sector.

Key Numbers

  • 333-284164 — SEC File Number (Identifies the specific registration statement)
  • 2836 — SIC Code (Indicates the company operates in the Biological Products sector)

Key Players & Entities

  • Maze Therapeutics, Inc. (company) — Registrant
  • January 30, 2025 (date) — Filing Date
  • Delaware (jurisdiction) — State of Incorporation
  • 171 Oyster Point Blvd., Suite 300 South San Francisco, California 94080 (address) — Principal Executive Offices
  • Jason Coloma, Ph.D. (person) — Chief Executive Officer

FAQ

What is the primary purpose of this S-1/A filing?

The S-1/A filing is an amendment to Maze Therapeutics, Inc.'s registration statement for its initial public offering, providing updated information to the SEC and potential investors.

When was this amendment filed?

This amendment was filed on January 30, 2025.

Where is Maze Therapeutics, Inc. incorporated?

Maze Therapeutics, Inc. is incorporated in Delaware.

Who is the Chief Executive Officer of Maze Therapeutics, Inc.?

Jason Coloma, Ph.D. is the Chief Executive Officer of Maze Therapeutics, Inc.

What is the company's principal executive office address?

The company's principal executive office is located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California 94080.

Filing Stats: 4,493 words · 18 min read · ~15 pages · Grade level 15 · Accepted 2025-01-30 06:57:41

Key Financial Figures

  • $15.00 — ial public offering price to be between $15.00 and $17.00 per share. We have applied
  • $17.00 — offering price to be between $15.00 and $17.00 per share. We have applied to list ou
  • $150 million — 1 to Shionogi for an upfront payment of $150 million and the potential for additional milest

Filing Documents

Risk factors

Risk factors 15 Special note regarding forward-looking statements 82

Use of proceeds

Use of proceeds 85 Dividend policy 87 Capitalization 88

Managements discussion and analysis of financial condition and results of operations

Managements discussion and analysis of financial condition and results of operations 94

Business

Business 115 Management 161

Executive compensation

Executive compensation 174 Certain relationships and related party transactions 189 Principal stockholders 193

Description of capital stock

Description of capital stock 196 Shares eligible for future sale 202 Material U.S. federal income tax consequences to non-U.S. holders 204

Underwriting

Underwriting 209 Legal matters 221 Experts 221 Where you can find additional information 221 Index to financial statements F-1 Through and including, 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription . Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. i Table of Contents For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. ii Table of Contents Prospectus summary This summary highlights selected information contained elsewhere in this prospectus and does not contain

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.